Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-168 Combined With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT07669415Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of LM-168 in solid tumor (advanced stage), sponsored by LaNova Medicines. Started Jul 2026; status: recruiting.
02
Drugs
LM-168
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07669415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07669415.